Thymosin beta-4 and TB-500 are often mentioned together. Before following a healing claim, identify the molecule.

Full-length thymosin beta-4 contains 43 amino acids. It helps regulate actin, a protein involved in cell shape and movement. That biology explains research interest; it does not make every related preparation equivalent.

A 2012 analytical study identified an acetylated seven-amino-acid fragment in material sold as TB-500. The FDA also warns that this common name has been used for different substances. A label alone cannot settle identity.

Human research has tested a defined thymosin beta-4 eye formulation for neurotrophic keratopathy, a disease in which the corneal surface struggles to heal.

In one randomized study, six of ten treated participants had complete healing at four weeks, compared with one of eight receiving placebo. The primary comparison had a P value of 0.0656, above the study's 0.05 threshold.

Later follow-up favored treatment, but the small study still calls for careful interpretation. Missing that threshold does not prove there was no benefit.

An eye formulation studied in a particular disease does not establish the benefits or safety of a different fragment used for muscle or tendon recovery.

The practical research habit is simple: match the molecule, formulation, population, and endpoint. Keep promising biology connected to the preparation actually tested.

World Peptide Foundation. Peptides in 2. Every experience matters.